Otsuka deal a salve for BMS
07 April 2009
Ian Haydock
Otsuka Pharmaceutical and
Bristol-Myers Squibb have extended their 1999 US agreement for Abilify (aripiprazole) until the product's expected loss of exclusivity in April 2015.
The firms will work together to promote BMS's leukaemia product Sprycel (dasatinib) in major markets, in a deal which...
Please Login to read the full article.
07 April 2009
Ian Haydock
The firms will work together to promote BMS's leukaemia product Sprycel (dasatinib) in major markets, in a deal which...
Please Login to read the full article.
RELATED CONTENT
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
